Pfizer Limited has announced its financial results for the quarter and half-year ended September 30, 2026. The company reported a net profit of ₹313.25 crore for the quarter and ₹517.72 crore for the half-year ended September 30, 2026. Revenue from operations for the quarter stood at ₹726.86 crore, and for the half-year, it was ₹1,380.03 crore. The results were approved by the Board of Directors on November 3, 2026.
Pfizer Limited Announces Strong Financial Performance for Q2 FY27
Pfizer Limited has disclosed its unaudited financial results for the second quarter and the first half of the financial year 2027, ending on September 30, 2026. The Board of Directors of the company approved these results following a meeting held on November 3, 2026.
Financial Highlights
For the quarter ended September 30, 2026, Pfizer Limited reported a net profit attributable to equity holders of ₹313.25 crore. This represents a significant increase compared to the corresponding period in the previous year. Revenue from operations for the quarter reached ₹726.86 crore.
The financial performance for the half-year ended September 30, 2026, also demonstrated robust growth. The net profit for this period stood at ₹517.72 crore, while revenue from operations amounted to ₹1,380.03 crore.
Exceptional Item Impact
An exceptional item of ₹132.06 crore has been reported for the quarter and half-year ended September 30, 2026. This relates to the discontinuation of the manufacture, marketing, distribution, and sale of Minipress XL by the company in the USA, resulting in a lump-sum payment from Pfizer Inc. USA. This payment is non-recurring in nature.
Balance Sheet Overview
As of September 30, 2026, Pfizer Limited’s total assets stood at ₹5,292.98 crore. The company’s total equity was ₹4,385.41 crore. Liabilities were reported at ₹907.57 crore.
Dividend Announcement
Shareholders approved a final dividend of ₹75 per equity share of ₹10 each (750%) for the financial year ended March 31, 2026. This dividend was paid on August 4, 2026.
The company continues to operate in a single segment, ‘Pharmaceuticals’, and has no subsidiary, associate, or joint venture companies as of September 30, 2026.
Source: BSE
